Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions

J Am Acad Dermatol. 2016 Jul;75(1):210-2. doi: 10.1016/j.jaad.2016.03.022.

Authors

Zachary Nahmias¹, Vinod E Nambudiri², Ruth Ann Vleugels³

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Grand Strand Regional Medical Center, Myrtle Beach, South Carolina.
³ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: [email protected].

PMID: 27317516
DOI: 10.1016/j.jaad.2016.03.022

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Humans
Immunologic Factors / therapeutic use*
Lenalidomide
Male
Middle Aged
Retreatment
Skin Diseases / drug therapy*
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use*

Substances

Immunologic Factors
Thalidomide
Lenalidomide